Ranibizumab (Lucentis) nový lék k léčbě vlhké formy věkem podmíněné makulární degenerace
| Title in English | Ranibizumb (Lucentris) a new agent to treat wet form of age related macular degeneration |
|---|---|
| Authors | |
| Year of publication | 2008 |
| Type | Article in Periodical |
| Magazine / Source | Praktické lékárenství |
| MU Faculty or unit | |
| Citation | |
| Web | odkaz na publikaci |
| Field | ORL, ophthalmology, stomatology |
| Keywords | ranibizumab; age related macular degeneration; vascular endothelial growth factor; intraocular injection into vitreous humor |
| Description | Ranibizumab (Lucentis) is a recombinant humanized fragment of a monoclonal antibody against vascular endothelial growth factor. It is administered by intraocular injection into the vitreous humor. It is indicated for treatment of the wet form of age related macular degeneration. It is produced in Escherichia coli cells using recombinant DNA technology. |